CHEK2

CHEK2
Name	Checkpoint kinase 2
Organism	Homo sapiens
Uniprot	O96017
Gene loc	22q12.1

CHEK2 is a serine/threonine-protein kinase that functions as a critical effector in the cellular DNA damage response, coordinating cell cycle arrest, DNA repair, and apoptosis. Discovered through studies linking chromosomal instability to cancer predisposition, it connects upstream sensors to downstream effectors across pathways implicated in oncogenesis and genome maintenance. Research on CHEK2 spans biochemical, genetic, clinical, and therapeutic domains involving collaborations among institutions such as National Institutes of Health, European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, Dana-Farber Cancer Institute and Broad Institute.

Function and Mechanism

CHEK2 operates as a kinase activated by phosphorylation in response to double-strand DNA breaks detected by sensor complexes involving MRE11, RAD50, NBN and the ATM kinase; activated CHEK2 phosphorylates substrates including p53, BRCA1, CDC25A, CDC25C and E2F1 to effect cell cycle checkpoints and apoptosis. Structural studies from groups at Max Planck Society, University of Cambridge, Harvard Medical School and Massachusetts Institute of Technology have elucidated oligomerization and FHA-domain-mediated substrate recognition that allow CHEK2 to bridge G1 and G2/M checkpoint control. Interactions with ubiquitin ligases such as MDM2 and DNA repair complexes including RAD51 and PALB2 position CHEK2 within networks studied at Wellcome Trust Sanger Institute and European Cancer Organisation. Biochemical assays developed by laboratories at Cold Spring Harbor Laboratory and Stanford University School of Medicine demonstrated ATP-binding and kinase activity modulated by autophosphorylation and protein–protein interactions characterized in publications from Cell, Nature, and Science.

Genetic Structure and Variants

The CHEK2 gene locus on chromosome 22q12.1 encodes multiple isoforms produced by alternative splicing identified in large-scale efforts by Human Genome Project collaborators and consortia such as 1000 Genomes Project and Exome Aggregation Consortium. Pathogenic alleles include truncating and missense variants—historically exemplified by the c.1100delC frameshift—reported in population studies from Iceland, Finland, United Kingdom, and United States cohorts. Large cancer genetics consortia including Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), The Cancer Genome Atlas (TCGA), and International Agency for Research on Cancer catalog variant frequencies and genotype–phenotype correlations. Functional assays developed at Sanger Institute and Cold Spring Harbor Laboratory differentiate loss-of-function from hypomorphic alleles; bioinformatics pipelines from European Bioinformatics Institute, Broad Institute, and National Center for Biotechnology Information annotate variants with clinical significance guidelines from American College of Medical Genetics and Genomics.

Role in Cancer and Disease Associations

Germline and somatic CHEK2 variants confer moderate penetrance for cancers including breast cancer, colorectal cancer, prostate cancer, thyroid cancer, and ovarian cancer as reported by multi-center studies led by Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Mayo Clinic. Epidemiological analyses from World Health Organization partner studies and population registries in Netherlands, Denmark, and France quantify relative risks and modifier effects alongside mutations in BRCA1, BRCA2, TP53, and mismatch repair genes characterized by the International Society for Gastrointestinal Hereditary Tumours. CHEK2-associated phenotypes extend to radiosensitivity and chromosomal instability described in case series from Johns Hopkins Hospital and mechanistic work at National Cancer Institute. Genome-wide association studies coordinated by Wellcome Trust and International HapMap Project explore interactions between CHEK2 variants and environmental exposures such as ionizing radiation assessed in cohorts from Chernobyl and occupational studies at Centers for Disease Control and Prevention.

Clinical Testing and Genetic Counseling

Clinical laboratories accredited by College of American Pathologists and regulatory frameworks from Food and Drug Administration and European Medicines Agency offer multigene panel testing including CHEK2, guided by management recommendations from National Comprehensive Cancer Network and genetic counseling standards from American Society of Human Genetics. Variant interpretation follows criteria from American College of Medical Genetics and Genomics with input from databases maintained by ClinVar, LOVD, and the ENIGMA consortium. Counseling emphasizes family history analyses using tools developed at King's College London and University of Toronto and integrates surveillance strategies from specialty societies such as American Society of Clinical Oncology and European Society for Medical Oncology.

Therapeutic Implications and Targeting

CHEK2 status informs therapeutic decision-making in contexts including PARP inhibitor sensitivity studied at AstraZeneca and Clovis Oncology clinical trials, and DNA-damage response targeting explored by translational teams at Genentech, Novartis, and academic centers like UCSF. Preclinical studies from Dana-Farber Cancer Institute and Cold Spring Harbor Laboratory assess CHEK2 synthetic lethality with ATR, WEE1, and CHK1 inhibitors, while consortium efforts at ClinicalTrials.gov-registered centers evaluate combination regimens. Pharmacogenomic resources at PharmGKB and drug development partnerships involving EORTC inform biomarker-driven trial design and precision oncology frameworks promoted by American Association for Cancer Research.

Model Organisms and Research Tools

Mouse models generated at The Jackson Laboratory and gene-targeting studies at Institut Pasteur and Riken recapitulate CHEK2 deficiency phenotypes including tumor susceptibility and genomic instability. Yeast models utilizing orthologous checkpoint kinases in studies from European Molecular Biology Laboratory and Cold Spring Harbor Laboratory provide conserved mechanistic insights; zebrafish and Drosophila systems at Max Planck Institute and University of Cambridge labs enable developmental and high-throughput screens. Research reagents and databases from Addgene, ATCC, OMIM, and UniProt support functional studies, while CRISPR toolkits from Broad Institute and high-throughput screening platforms at Wellcome Trust Sanger Institute accelerate variant functionalization and drug discovery.

Category:Human proteins